RxDoctor Payments Data

Sapna Legha, MD

Cardiovascular Disease · Shenandoah, TXNPI 1073899506

Payments from drug & device makers

$5,231in general payments, 2019–2025

Across 154 payments — averaging $33.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Abiomed$962
  • Merck$340
  • Boston Scientific$307
  • Novartis$267
  • Impulse Dynamics (USA) Inc.$255
  • plus $2K from 35 others

What the payments were for

  • Travel & lodging$55011%
  • Food & beverage$4,68189%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,231 in reported general payments places this provider in the 55th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$219,370
Medicare patients
563
Services billed
2,118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban140$132,291
EntrestoSacubitril/Valsartan141$117,534
JardianceEmpagliflozin89$90,878
FarxigaDapagliflozin Propanediol65$65,662
XareltoRivaroxaban30$24,424
Repatha SureclickEvolocumab23$15,719
Valganciclovir Hcl14$9,761
Tacrolimus27$9,043
Sildenafil Citrate28$5,708
Voriconazole13$5,120
Mycophenolate Mofetil21$4,281
Metoprolol Succinate236$2,847
Ranolazine ErRanolazine26$2,482
Digoxin123$2,444
Torsemide92$2,081

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$267$117,534141 claims
Boehringer IngelheimJardiance$120$90,87889 claims
AstraZenecaFarxiga$57$65,66265 claims
Johnson & JohnsonXarelto$15$24,42430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Shenandoah

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →